Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., ...
Merck Animal Health, a division of Merck & Co., Inc. (MRK), Tuesday announced the expansion of Nobivac NXT vaccine platform with the ...
The technological innovation is an expansion of the NOBIVAC NXT platform, and a breakthrough achievement against one of the ...
Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...
This week’s quarterly results from Merck looked pretty good, all things considered: Sales and earnings came in ahead of Wall ...
A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.
Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...
Merck lowered 2024 EPS guidance down to $7.94 to $8.03, from its previous guidance of $8.53 to $8.65. The new guidance reflects the negative impact of a one-time charge of $1.3 billion or 51 cents ...
The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers. The FDA approves MRK's Keytruda for first-line ...
The Merck Future Insight prize was established on the occasion of Merck’s 350th anniversary in 2018 to honour and enable pioneering scientists who are striving to solve some of the biggest ...
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...